Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)



Status:Recruiting
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:5/5/2014
Start Date:November 2011
End Date:October 2016
Contact:Toll Free Number
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination With Chemotherapy in Subjects With Refractory or Recurrent Acute Myelogenous Leukemia (Protocol No. P07649 (005))

This is a study of MK-8242 alone and in combination with cytarabine in adult participants
with refractory or recurrent acute myelogenous leukemia (AML). The study will have 2 Arms.
Arm A is for participants with refractory or recurrent AML who are considered ineligible for
standard chemotherapy. In Part 1 of Arm A, participants will receive MK-8242 monotherapy in
escalating doses to determine the recommended phase 2 dose [RP2D]. In Part 2, participants
will receive monotherapy with MK-8242 to confirm the RP2D and assess preliminary efficacy.
Arm B is for participants with recurrent AML following an initial complete remission (CR) or
CR with incomplete marrow recovery (CRi) of 6 to 12 months duration. In Part 1 of Arm B,
participants will receive MK-8242 + cytarabine in escalating doses to determine the RP2D in
combination with cytarabine. In Part 2, participants will receive MK-8242 + cytarabine to
confirm the RP2D and assess preliminary efficacy. The pharmacokinetics of MK-8242 will be
studied in both arms. With Amendment 4 (22 August 2013) a 21-day dosing cycle is added, with
MK-8242 being given on Days 1-7 of each 21-day cycle in both the monotherapy and combination
therapy arms; data from Arm A will be used to determine whether a participant receives
21-day or 28-day therapy in Arm B.


Inclusion criteria:

- For Arm A Part 1 (monotherapy/dose escalation): refractory or recurrent AML, not an
appropriate candidate for standard therapy

- For Arm A Part 2 (monotherapy/dose confirmation/cohort expansion): refractory or
recurrent AML, not an appropriate candidate for standard therapy, and have wild type
TP53 gene mutation analysis

- For Arm B Part 1 (combination therapy/dose escalation): recurrent AML having achieved
an initial CR or CRi of 6-12 months duration and age ≥18 years old and <70 years old

- For Arm B Part 2 (combination therapy/dose confirmation/cohort expansion): recurrent
AML having achieved an initial CR or CRi of 6-12 months duration, age ≥18 years old
and <70 years old, and have wild type TP53 gene mutation analysis

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 for all
Arm A, or 0 or 1 for all Arm B

- Negative pregnancy test within 72 hours of the first dose of study medication

- Female participants and male participants and their partners who are of childbearing
potential must agree to abstain from sexual intercourse or to use an acceptable
method of contraception during the study and for 90 days following the last dose of
study therapy

- Adequate organ function

- Recovered from the effects of any prior surgery, radiotherapy or anti-neoplastic
treatment, with the exception of alopecia

- Must be able to swallow, retain, and absorb oral medications and oral nutrition

- Must follow the appropriate washout period for prohibited treatments

Exclusion criteria:

- Active malignancy other than AML

- Leptomeningeal leukemia requiring intrathecal therapy

- For Arm A and B, Part 1 only: history of myelodysplastic syndrome (MDS)

- For Arm A and B, Part 2: AML in the background of MDS may be included

- Isolated extramedullary leukemia without also meeting bone marrow criteria for acute
leukemia

- AML blast crisis of chronic myelogenous leukemia (CML)

- Bone marrow transplant with active graft-versus host disease (GVHD) or who receives
immunosuppressive therapy

- Uncontrolled active infection that requires systemic treatment

- Clinically significant hepatitis at Screening, or hepatitis C antibody positive,
hepatitis B surface antigen positive, or human immunodeficiency virus (HIV)
seropositive

- Persistent, unresolved, drug-related toxicity

- Breast-feeding, pregnant, intends to become pregnant or intends to breast feed during
the study or has a positive pregnancy test at Screening

- A person participating in any other clinical study with a potentially therapeutic
agent or who has received another investigational product within 5 half-lives (if the
half-life is known) or 28 days (if the half-life is unknown) prior to Day 1 of cycle
1

- A participant who, within the past 6 months, has had any of the following: myocardial
infarction, coronary/peripheral artery bypass graft, cerebrovascular accident,
transient ischemic attack, or uncontrolled seizure disorder (i.e., seizures within
the past 6 months)

- A participant who, at the time of Screening, presents with: unstable or uncontrolled
angina, New York Heart Association (NYHA) class III or IV congestive heart failure,
uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically
significant electrocardiogram (ECG) abnormality

- Known bleeding disorder, e.g. hemophilia or disseminated intravascular coagulopathy
or on anti-coagulation therapy

- For Arm B only: Known hypersensitivity to cytarabine
We found this trial at
5
sites
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials